IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4117
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$10M
William T. Ho
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, which is in Phase I clinical trial for glioblastoma and solid tumors. InB-100, an allogeneic product candidate, is in clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$INAB IN8BIO, INC. | 35 | 23 | 23 | 59 | - | - | -163.7% | -128.7% | - | -11006.4% | -11006.4% | 88.3% | 0.0% | 27.0x | $10M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
IN8BIO, INC. (INAB) receives a "Avoid" rating with a composite score of 34.9/100. It ranks #4117 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
William T. Ho
Chief Executive Officer
Labor Force
20
23
25
13
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for INAB
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for INAB.
View All RatingsHigh margin volatility — erratic forensic earnings quality
ROE proxy -163.7% (sector -2.5%)
GM N/A vs sector 43%, OM -11006% vs sector 1%
Capital turnover N/A, R&D intensity 2291.8%
Rev growth 88%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags IN8BIO, INC. with an Avoid rating, assigning a composite score of 34.9/100 and 1 out of 5 stars. Ranked #4117 of 7,333 stocks, INAB falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
IN8BIO, INC. registers a weak quality score of just 23/100, indicating significant profitability challenges. The company reports a return on equity of -163.7% (sector avg: -2.5%), net margins of -11006.4% (sector avg: -0.2%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
INAB registers a value score of just 23/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.15x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
IN8BIO, INC.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 88.3% vs. a sector average of 5.9% and a return on assets of -128.7% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
INAB demonstrates moderate momentum with a score of 59/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 88.3% year-over-year, while a beta of 9.81 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
IN8BIO, INC. registers a low stability score of 13/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 9.81 and a debt-to-equity ratio of 27.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 53/100 for INAB suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 9.81), elevated leverage (D/E: 27.00x), micro-cap liquidity risk. With a $10M market cap (micro-cap), IN8BIO, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
IN8BIO, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4117 of 7,333 overall (44th percentile). Key comparisons include ROE of -163.7% trailing the -2.5% sector median and operating margins of -11006.4% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While INAB currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (13) would have the largest impact on the composite score.
ROE 6499% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 853308% BELOW SECTOR MEDIAN
Debt/Equity 13400% ABOVE SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate IN8BIO, INC. (INAB) as Avoid with a composite score of 34.9/100 at a current price of $1.59. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (59th percentile) and investment (25th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (13th percentile) and value (23th percentile) tempers our overall conviction. We assign a No Moat rating (33/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: sustainability of the current growth rate; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
IN8BIO, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.9/100 places it at rank #4117 in our full 7,333-stock universe. At $10M in market capitalization, IN8BIO, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 88%, though momentum at the 59th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
Available margin data shows operating margins of -11006%. Incomplete margin data limits our ability to fully assess the cost structure and margin trajectory, though the available metrics provide a partial view of operating efficiency.
At a current price of $1.59, IN8BIO, INC. is trading at a premium to fundamental value. Our value factor score of 23/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 1.1x, P/S of 42.9x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Revenue growth of 88% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (27% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 34.9/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -11006.4% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Below-average quality (23th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Very High uncertainty rating to IN8BIO, INC.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 9.81), current negative profitability (net margin -11006.4%), below-average price stability (13th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 9.81); current negative profitability (net margin -11006.4%); below-average price stability (13th percentile); weak quality scores (23th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 13th percentile and quality factor at the 23th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (27% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate IN8BIO, INC.'s capital allocation as Poor. Key concerns include low returns on equity (-163.7%), negative profitability, weak asset returns (ROA -128.7%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — IN8BIO, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, IN8BIO, INC. receives a Avoid rating with a composite score of 34.9/100 (rank #4117 of 7,333). Our quantitative framework assigns a No Moat (33/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 28/100.
Our analysis does not support a constructive view on IN8BIO, INC. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign IN8BIO, INC. a meaningful economic moat, scoring 33/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 8.8/20.
The strongest moat sources are growth durability (8.8/20) and financial resilience (8.6/20). Rev growth 88%, 5yr history. Interest coverage N/A. These pillars form the core of IN8BIO, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and margin superiority (6.5/20). ROE proxy -163.7% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect IN8BIO, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include robust top-line growth of 88% expanding the revenue base. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 23th percentile.
The margin profile shows operating margins of -11006%, net margins of -11006.4%. Return metrics include ROE of -163.7% and ROA of -128.7%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -163.7% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 27%, revenue growth of 88%. The sector median D/E is 0%, putting IN8BIO, INC. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
High beta of 9.81 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081